Experiment Protocol Biomedical Engineer in Spain Madrid –Free Word Template Download with AI

This Experiment Protocol outlines the procedures for evaluating a novel biomedical device designed for continuous glucose monitoring (CGM). The study will be conducted in Madrid, Spain, under the supervision of a team of Biomedical Engineers and medical professionals. The primary objective is to assess the accuracy, reliability, and safety of the device in a clinical setting, ensuring compliance with Spanish and European regulations.

The main objectives of this experiment are:

• To evaluate the accuracy of the CGM device compared to standard blood glucose measurements.
• To assess the device's performance over a 14-day period in real-world conditions.
• To identify any adverse events or safety concerns associated with the device.
• To gather user feedback on the device's usability and comfort.

The experiment will follow a randomized controlled trial (RCT) design. Participants will be recruited from diabetes clinics in Madrid, Spain. The study will involve two groups: a control group using a standard CGM device and an experimental group using the novel device.

3.1 Participant Selection

Inclusion criteria:

• Age between 18 and 75 years.
• Diagnosed with Type 1 or Type 2 diabetes.
• Willing to provide informed consent.

Exclusion criteria:

• Pregnancy or breastfeeding.
• Severe renal or hepatic impairment.
• History of adverse reactions to similar devices.

4.1 Device Application

The CGM device will be applied to the participant's upper arm by a trained Biomedical Engineer. The device will be calibrated according to the manufacturer's instructions.

4.2 Data Collection

Participants will record their blood glucose levels using a standard glucometer at least four times a day. The CGM device will continuously monitor glucose levels and transmit data to a secure server.

4.3 Follow-Up

Participants will attend weekly follow-up appointments to review their data and report any issues. At the end of the 14-day period, participants will complete a questionnaire on their experience with the device.

Data will be analyzed using statistical software. The accuracy of the CGM device will be assessed using the Mean Absolute Relative Difference (MARD) metric. Safety data will be reviewed for any adverse events.

This study will be conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Universidad Politécnica de Madrid. Informed consent will be obtained from all participants.

The experiment will comply with the regulations set by the Spanish Agency for Medicines and Medical Devices (AEMPS) and the European Medicines Agency (EMA).

This Experiment Protocol provides a comprehensive framework for evaluating the novel CGM device in Madrid, Spain. By adhering to strict ethical and regulatory standards, the study aims to contribute valuable insights to the field of Biomedical Engineering and improve diabetes management.